Behind the Scenes of PTC Therapeutics's Latest Options Trends - PTC Therapeutics ( NASDAQ:PTCT )
High-rolling investors have positioned themselves bullish on PTC Therapeutics PTCT, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
PTCT Earnings Beat but Sales Drop 4%
Ptc Therapeutics ( NASDAQ:PTCT ) , a biopharmaceutical company specializing in therapies for rare diseases, released its second quarter 2025 earnings on August 7, 2025. The main headline was a beat on both revenue and GAAP earnings per share, despite an overall year-over-year revenue decline.
PTC Therapeutics ( PTCT ) Reports Q2 Loss, Beats Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics ( PTCT ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics ( PTCT ) Surges 11.2%: Is This an Indication of Further Gains?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Why Is PTC Therapeutics Stock Trading Higher Today? - PTC Therapeutics ( NASDAQ:PTCT )
Sephience is approved for sepiapterin-responsive PKU in patients 1 month and older. Wholesale cost is $40,000 a month; U.S. launch starts in August, targeting 1,200 prescribers. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. The U.S.
These Analysts Increase Their Forecasts On PTC Therapeutics - PTC Therapeutics ( NASDAQ:PTCT )
PTC Therapeutics, Inc. PTCT announced it has gained FDA approval for SEPHIENCE on Monday. "We are excited to have reached this important milestone for those affected by PKU," said Matthew B.
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026.
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress - uniQure ( NASDAQ:QURE )
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~
Strength Seen in MiMedx ( MDXG ) : Can Its 8.0% Jump Turn into More Strength?
MiMedx (MDXG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ...
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer - uniQure ( NASDAQ:QURE )
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 ( GLOBE NEWSWIRE ) -- uniQure N.V.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT - PTC Therapeutics ( NASDAQ:PTCT )
NEW YORK, June 06, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ( "PTC" or the "Company" ) PTCT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
All You Need to Know About PTC Therapeutics ( PTCT ) Rating Upgrade to Buy
PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy ( SMA )
Basel, 04 June 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the European Commission ( EC ) has approved a label extension for Evrysdi® ( risdiplam ) to include a new, room-temperature stable tablet for people living with spinal muscular atrophy ( SMA ) .
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT - PTC Therapeutics ( NASDAQ:PTCT )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ( "PTC" or the "Company" ) PTCT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Churchill Downs ( NASDAQ:CHDN ) , DBV Technologies ( NASDAQ:DBVT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Ascendiant Capital raised Pro-Dex, Inc. PDEX price target from $54 to $56.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT - PTC Therapeutics ( NASDAQ:PTCT )
NEW YORK, May 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ( "PTC" or the "Company" ) PTCT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday - National Vision Holdings ( NASDAQ:EYE ) , CVRx ( NASDAQ:CVRX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Tycho Peterson upgraded the rating for GeneDx Holdings Corp.
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday - Arista Networks ( NYSE:ANET ) , Amylyx Pharmaceuticals ( NASDAQ:AMLX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised BlackLine, Inc. BL price target from $46 to $50.
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Amylyx Pharmaceuticals ( NASDAQ:AMLX ) , Bank First ( NASDAQ:BFC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Leerink Partners analyst Marc Goodman upgraded the rating for Amylyx Pharmaceuticals, Inc.
PTC Therapeutics ( PTCT ) Q1 2025 Earnings Call
Image source: The Motley Fool.Tuesday, May 6, 2025 at 4:30 p.m. ETChief Executive Officer - Matthew KleinContinue reading ...
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - PTC Therapeutics ( NASDAQ:PTCT )
39% reduction in HTT protein seen at 10mg dose in Stage 2 Huntington's patients. Plasma NfL dropped by 14% at 10mg dose after 24 months ( nominal p=0.03 ) . Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on. PTC Therapeutics, Inc.
Crude Oil Falls Over 2%; ISM Services PMI Rises In April - Hyperscale Data ( AMEX:GPUS ) , BioCryst Pharma ( NASDAQ:BCRX )
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday. The Dow traded up 0.21% to 41,406.25 while the NASDAQ fell 0.41% to 17,903.64. The S&P 500 also fell, dropping, 0.26% to 5,671.90. Industrials shares rose by 0.2% on Monday.
Krystal Biotech, Inc. ( KRYS ) Earnings Expected to Grow: Should You Buy?
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
PTC Therapeutics ( PTCT ) Earnings Expected to Grow: Should You Buy?
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder - PTC Therapeutics ( NASDAQ:PTCT )
The European Commission upheld CHMP's opinion, ending Translarna's conditional marketing authorization for nmDMD in the EU. Translarna's 2024 net revenue was $339.9M, down from $355.8M in 2023, while PTC submitted four FDA applications, all accepted for review.
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - PTC Therapeutics ( NASDAQ:PTCT )
Over 97% of patients in the APHENITY study increased protein intake by 126% while on sepiapterin treatment. PTC expects FDA approval for sepiapterin by July 29, 2025, with regulatory decisions in Europe and Japan later in the year.
Novartis Reports Updated Positive Data From Phase III SMA Program
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association ( MDA ) 2025 conference
Basel, 17 March 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that it will present new data at the Muscular Dystrophy Association ( MDA ) conference, 16-19 March, 2025, in Dallas, Texas, from its neuromuscular portfolio, including 12 oral and poster presentations.
This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - CenterPoint Energy ( NYSE:CNP ) , Capital One Finl ( NYSE:COF )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Kiniksa Pharmaceuticals ( KNSA ) Soars 5.8%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.
PTC Therapeutics ( PTCT ) Reports Q4 Loss, Lags Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75% and 3.96%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Countdown to PTC Therapeutics ( PTCT ) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
PTC Therapeutics ( PTCT ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis ( EXEL ) Q4 Earnings and Revenues Top Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 7.84% and 0.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.
PTC Therapeutics ( PTCT ) Moves 9.0% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain
NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides an encouraging outlook for 2025.
Novartis to Report Q4 Earnings: What's in the Offing?
NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder - Novartis ( NYSE:NVS )
AstraZeneca' s Ultomiris ( ravulizumab ) and Soliris ( eculizumab ) are commonly used anti-C5 therapies. In the study, the safety profile of Fabhalta monotherapy was consistent with previously reported data. Get Monthly Picks of Market's Fastest Movers
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.
Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday - Bank of America ( NYSE:BAC ) , Salesforce ( NYSE:CRM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keefe, Bruyette & Woods raised the price target for Bank of America Corporation BAC from $50 to $57.
